• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Encourages Use of New Endpoints in Trials of Opioid Abuse Treatments

FDA Encourages Use of New Endpoints in Trials of Opioid Abuse Treatments

October 5, 2020

Sponsors of opioid use disorder (OUD) treatments should expand their trials beyond collecting evidence for an NDA submission and gather data on additional clinically meaningful outcomes the FDA considers “highly valuable,” according to a final guidance the agency released last week.

A change in drug-use pattern, particularly abstinence, is typically used as a primary endpoint for OUD treatment trials, according to the guidance, but the FDA is interested in expanding primary and secondary endpoints to include outcome measures “important to patients and their families, clinicians and the public.”

Additional endpoints could include reduction in such adverse outcomes as mortality, need for emergency medical intervention, and hepatitis C infection or reinfection. The guidance also recommends endpoints focusing on change in disease status as measured by standard diagnostic criteria, patient-reported effects on feeling or function (e.g., reduction in intensity of the urge to use opioids) or reduction of opioid use below a clinically significant level.

Sponsors can propose other endpoints, the guidance says, and can study several endpoints or composite endpoints in one trial.

The guidance is virtually unchanged from the August 2018 draft save for a new section on benefit-risk considerations that suggests trials of products associated with a risk of serious adverse events present “compelling demonstrations of clinical benefit” that outweigh the risk. If the investigational drug itself has abuse potential, the guidance says the FDA will consider its positive and negative public health effects, including its effect on nonpatients, such as members of the patient’s household.

Drugs intended to provide relief of withdrawal symptoms are not covered by the guidance, the FDA says, because they usually are not sufficient to reduce the risk of returning to opioid abuse.

To read the guidance, click here: https://bit.ly/3lcHLWf.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing